Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5967-5973

  Shiraga, Minoru ^a   Yano, Seiji ^a   Yamamoto, Akihiko ^a   Ogawa, Hirohisa ^a   Goto, Hisatsugu ^a   Miki, Toyokazu ^a   Miki, Keisuke ^a   Zhang, Helong ^a   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY; LIVER; LUNG CANCER; LUNG NODULE; LYMPH NODE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE;

ADENOCARCINOMA; ANIMALS; CARCINOMA, SQUAMOUS CELL; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; MICE; MICE, SCID; NEOPLASM METASTASIS; PHENYL ETHERS; PROTEASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0037108864     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Stetler-Stevenson, W. G., Hewitt, R., and Corcoran, M. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin. Biol., 7: 147-154, 1996
2. Nelson, A. R., Fingleton, B., Rothenberg, M. L., and Matrisian, L. M. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol., 18: 1135-1149, 2000
3. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajer, O. L., Cherard, M. P., Rio, M., C., and Chamborn, P., A novel metalloproteinases gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond.), 348: 699-704, 1990
4. Kanayama, H., Yokota, K., Kurokawa, Y., Murakami, Y., Nishitani, M., and Kagawa, S., Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer (Phila.), 82: 1359-1363, 1998
5. Murrer, D., Breathnach, R., Engelman, A., Millon, R., Bronner, G., Flesch H., Dumont, P., Eber, M., and Abecasis, J. Expression of collagenase related metalloproteinases genes in human lung or head and neck tumors. Int. J. Cancer. 48: 550-556, 1991
6. Sakata, K., Shigemasa, K., Nagai, N., and Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int. J. Oncol., 17: 673-681, 2000
7. r 92, 000 type IV collagenase in brain tumors. Cancer Res., 53 (10 Suppl): 2208-2211, 1993
8. Murray, G. I., Duncan, M. E., O'Neil, P., Melvin, W. T., and Fothergill, J. E. Matrix metalloproteinases-1 is associated with poor prognosis in colorectal cancer. Nat. Med., 2: 461-462, 1996
9. Brown, P. D., Bloxidge, RE., Stuart, N. S. E., Gatter, K., C., and Carmichale, J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in no-small-cell lung carcinoma. J. Natl. Cancer Inst. (Bethesda), 85: 574-578, 1993
10. Herbst, R. S., Yano, S., Kuniyasu, H., Khuri, F. R., Bucana, C. D., Guo, F., Liu, D., Kemp, B., Lee, J. J., Hong, W. K., and Fidler, I. J. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage 1 non-small cell lung carcinoma. Clin. Cancer Res., 6: 790-797, 2000
11. Zucker, S., Cao, J., and Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene, 19: 6642-6650, 2000
12. Yano, S., Nishioka, Y., Izumi, K., Tsuruo, T., Tanaka, M., Miyasaka, M., and Sone, S. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int. J. Cancer, 67: 211-217, 1996
13. Yano, S., Shinohara, H., Herbst, R. S., Kuniyasu, H., Bucana, C. D., Ellis, L. M., and Fidler, I. J. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. J. Pathol., 157: 1893-1903, 2000
14. Yamada, A., Uegaki, A., Nakamura, T., Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm. Res., 49: 144-146, 2000
15. Shrivastava, P., Hanibuchi, M., Yano, S., Parajuli, P., Tsuruo, T., and Sone, S., Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil. Cancer Chemother. Pharmacol., 42: 483-490, 1998
16. Verheijen, J. H., Nieuwenbroek, N. M., Beekman, B., Hanemaaijer, R., Verspaget, H. W., Ronday, H. K., and Bakker, A. H. Modified proenzymes as artificial substrates for proteolytic enzymes: Colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem. J., 323: 603-609, 1997
17. Giambernardi, T. A., Grant, G. M., Taylor, G. P., Hay, R. J., Maher, V. M., McCormick, J. J., and Klebe, R. J. Overview of matrix metalloproteinase expression in culture human cells. Matrix Biol., 16: 483-496, 1998
18. Ikeda, M., Maekawa, R., Tanaka, H., Matsumoto, M., and Yoshioka, T., Inhibition of gelatinolytic metalloproteinases inhibitor: Application of film in situ zymography. Clin. Cancer Res., 6: 3290-3296, 2000
19. Hidalgo, M., and Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. (Bethesda), 93: 178-193, 2001
20. Eccles, S. A., Box, G. M., Court, W. J., Bone, E. A., Thomas, W., and Brown, P. D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res., 56: 2815-2822, 1996
21. Nokihara, H., Yano, S., Nishioka, Y., Hanibuchi, M., Higashida, T., Tsuruo, T., and Sone, S. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein expressing human small cell lung cancer cells. Jpn. J. Cancer Res., 92: 785-792, 2001
22. Bu. W., Tang, Z. Y., Sun, F. X., Ye, S. L., Liu, K. D., Xue, Q., Chen, J., and Gao, D. M. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology, 45: 1056-1061, 1998
23. Naito, K., Kanbayashi, N., Nakajima, M., Murai, T., Arakawa, K., Nishimura, S., and Okuyama, A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int. J. Cancer, 58: 730-735, 1994
24. Prontera, C., Mariani, B., Rossi, C., Poggi, A. K., and Rotilio, D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int. J. Cancer, 31: 761-766, 1999
25. Della Porta, P., Soeltl, R., Krell, H. W., Collins, K., O'Donoghue, M., Schmitt, M., and Kruger, A. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res., 19: 3809-3816, 1999
26. Kruger, A., Soeltl, R., Sopov, I., Kopitz, C., Arlt, M., Magdolen, V., Harbeck, N., Gansbacher, B., and Schmitt, M. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res., 61: 1272-1275, 2001
27. Matsushita, A., Onda, M., Uchida, E., Maekawa, R., and Yoshioka, T. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer. Int. J. Cancer, 92: 434-440, 2001
28. Ohta, M., Konno, H., Tanaka, T., Baba, M., Kamiya, K., Oba, K., Kaneko, T., Syouji, T., Igarashi, A., and Nakamura, S. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Jpn. J. Cancer Res., 92: 688-695, 2001